TAVNEOS SIDE EFFECTS

  • Generic Name: avacopan capsules
  • Brand Name: Tavneos
Last updated on MDtodate: 10/12/2022

SIDE EFFECTS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

  • Hepatotoxicity
  • Hypersensitivity Reactions
  • Hepatitis B Virus (HBV) Reactivation
  • Serious Infections

Clinical Trials Experience

Because the clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The identification of potential adverse drug reactions was based on safety data from the phase 3 clinical trial in which 330 patients with ANCA-associated vasculitis were randomized 1:1 to either TAVNEOS or prednisone. The mean age of patients was 60.9 years (range of 13 to 88 years), with a predominance of men (56.4%) and Caucasians (84.2%). The cumulative exposure to TAVNEOS was 138.7 patient-years. Additionally, two phase 2 trials were conducted in ANCA-associated vasculitis. The cumulative clinical trial exposure from the phase 2 and 3 trials equals 212.3 patient-years.

The most frequent serious adverse reactions reported more frequently in patients treated with TAVNEOS than with prednisone were pneumonia (4.8% TAVNEOS vs. 3.7% prednisone), GPA (3.0% TAVNEOS vs. 0.6% prednisone), acute kidney injury (1.8% TAVNEOS vs. 0.6% prednisone), and urinary tract infection (1.8% TAVNEOS vs. 1.2% prednisone). Within 52 weeks, 4 patients in the prednisone treatment group (2.4%) and 2 patients in the TAVNEOS group (1.2%) died. There were no deaths in the phase 2 trials.

In the phase 3 trial, seven patients (4.2%) in the TAVNEOS treatment group and 2 patients (1.2%) in the prednisone treatment group discontinued treatment due to hepatic-related adverse reactions, including hepatobiliary adverse reactions and liver enzymes abnormalities. The most frequent adverse reaction that led to drug discontinuation reported by > 1 patient and more frequently reported in patients treated with TAVNEOS was hepatic function abnormal (1.8%).

The most common adverse reactions that occurred in ≥5% of patients and higher in the TAVNEOS group as compared with the prednisone group are listed in Table 1.

Table 1: Adverse Reactions Reported in ≥5% of Patients and Higher in TAVNEOS Group vs. Prednisone Group in Phase 3 Trial

Adverse Reaction Prednisone
(N=164) n (%)
TAVNEOS
(N=166) n (%)
Nausea 34 (20.7) 39 (23.5)
Headache 23 (14.0) 34 (20.5)
Hypertension 29 (17.7) 30 (18.1)
Diarrhea 24 (14.6) 25 (15.1)
Vomiting 21 (12.8) 25 (15.1)
Rash 13 (7.9) 19 (11.4)
Fatigue 15 (9.1) 17 (10.2)
Upper abdominal pain 10 (6.1) 11 (6.6)
Dizziness 10 (6.1) 11 (6.6)
Blood creatinine increased 8 (4.9) 10 (6.0)
Paresthesia 7 (4.3) 9 (5.4)
N=number of patients randomized to treatment group in the Safety Population; n=number of patients in specified category.

 

Hepatotoxicity And Elevated Liver Function Tests

In the phase 3 trial, a total of 19 patients (11.6%) in the prednisone group and 22 patients (13.3%) in the TAVNEOS group had hepatic-related adverse reactions, including hepatobiliary adverse reactions and liver enzyme abnormalities. Study medication was paused or discontinued permanently due to hepatic-related adverse reactions in 5 patients (3.0%) in the prednisone group and 9 patients (5.4%) in the TAVNEOS group. Serious hepatic-related adverse reactions were reported in 6 patients (3.7%) in the prednisone group and 9 patients (5.4%) in the TAVNEOS group. A serious hepatic-related adverse reaction was reported in 1 patient in the TAVNEOS group in the phase 2 studies.

Angioedema

In the phase 3 trial, 2 patients (1.2%) in the TAVNEOS group had angioedema; one event was a serious adverse reaction requiring hospitalization.

Elevated Creatine Phosphokinase

In the phase 3 trial, 1 patient (0.6%) in the prednisone group and 6 patients (3.6%) in the TAVNEOS group had increased creatine phosphokinase. One TAVNEOS-treated patient discontinued treatment due to increased creatine phosphokinase.

 

SRC: NLM .